Is there a link between endothelial dysfunction, coagulation activation and nitric oxide synthesis in preeclampsia?  by Dusse, Luci Maria et al.
Clinica Chimica Acta 415 (2013) 226–229
Contents lists available at SciVerse ScienceDirect
Clinica Chimica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /c l inch imIs there a link between endothelial dysfunction, coagulation activation and nitric
oxide synthesis in preeclampsia?
Luci Maria Dusse a,⁎, Patrícia Nessralla Alpoim a, Bashir A. Lwaleed b, Lirlândia Pires de Sousa a,
Maria das Graças Carvalho a, Karina Braga Gomes a
a Faculty of Pharmacy, Universidade Federal de Minas Gerais, Brazil
b Faculty of Health Sciences, University of Southampton, Southampton, UK⁎ Corresponding author at: Faculty of Pharmacy, Bl 3
of Minas Gerais, Av. Antonio Carlos, 6627, Belo H
31270-901, Brazil.
E-mail address: lucidusse@gmail.br (L.M. Dusse).
0009-8981 © 2012 Elsevier B.V.
http://dx.doi.org/10.1016/j.cca.2012.10.006
Open access under the Elsea b s t r a c ta r t i c l e i n f oArticle history:
Received 30 March 2012
Received in revised form 20 September 2012
Accepted 4 October 2012
Available online 23 October 2012
Keywords:
Preeclampsia
Thrombomodulin
D-Dimer
Nitric oxide
NOS activity
cGMP
Background: There may be a relationship between endothelial dysfunction, coagulation activation and nitric
oxide (NO) synthesis in women with mild and severe preeclampsia (PE).
Methods: Plasma thrombomodulin (TM), D-Dimer (D-Di), cyclic guanosine monophosphate (cGMP) and
placental nitric oxide synthase activity (NOS) were investigated in 21 normotensive pregnant women
(G1), 22 pregnant women with mild PE (G2) and 20 pregnant women with severe PE (G3).
Results: TM and D-Di were signiﬁcantly increased in G3 compared to G1 (P=0.001 and P=0.006, respectively)
and G2 (P=0.001, in both cases). However, there was no signiﬁcant difference when G1 was compared to G2.
For total NOS, calcium independent NOS, calcium dependent NOS no signiﬁcant difference was observed
among the groups studied.
Conclusions: TM and D-Di levels are raised in women with severe PE compared to normotensive pregnant
women and women with mild PE. While increased TM levels may reﬂect endothelial dysfunction, raised D-Di
levels indicate a hypercoagulable state. NO assessed by 2 indirect methods did not show any signiﬁcant differ-
ence among the groups studied. Due to current limitations with in vitro NO measurements and interferences
associated with NO bioavailability, particularly in PE, such ﬁndings should not be over-interpreted. © 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Preeclampsia (PE) is a major cause of maternal mortality, morbid-
ities, perinatal death, preterm birth and intrauterine growth restriction
[1]. It is associated with generalized vasoconstriction, endothelial
activation [2–4], ﬁbrin deposition [5] and inﬂammation [6]. However,
PE etiology remains poorly understood.
Thrombomodulin (TM) is a transmembranous glycoprotein ex-
pressed in a variety of cells and tissues in adults and during develop-
ment. Endothelial injury results in TM release [7]. D-dimer (D-Di) is a
unique fragment of ﬁbrin degradation products. It is produced when
cross-linked ﬁbrin is lysed by plasmin. High D-Di levels indicate ﬁbrin
formation and plasmin activation [8].
Nitric oxide (NO) is an endothelium derived messenger responsible
for vascular tone regulation. It is synthesized from L-arginine by
NO-synthase (eNOS) and co-factors yielding equimolar quantity of
L-citrulline. NO leaves endothelial cells to smoothmuscle cells, activates
guanylate cyclase and converts guanosine triphosphate to cyclic guano-
sine monophosphate (cGMP). A high level of cytoplasmatic cGMPRoom 4104, Federal University
orizonte, Minas Gerais. CEP:
vier OA license.results in Ca+2 reduction, leading to vasodilatation andplatelet activation
inhibition [9]. NO is involved in various stages of pregnancy including
implantation, maintenance of uterine acquiescence during pregnancy,
control of uterine contractions and relaxation, basic physiological adop-
tion for successful gestation and regulation of blood pressure [10].
Reduced NO may contribute to hypertension, endothelial dysfunc-
tion and coagulation activation, commonly seen in PE. In the present
study we investigate the relationship between endothelial injury, coag-
ulation activation and NO synthesis in normotensive pregnant women
with mild and severe PE.
2. Methods
2.1. Subjects
Ethical committee approval was granted for the study by the
Universidade of Federal de Minas Gerais, Brazil. Informed consent was
sought from all participants and the relevant clinical details were collect-
ed. A total of 63 women were recruited from Maternidade Odete
Valadares/BeloHorizonte-Brazil. These includeG1=normotensive preg-
nantwomen (N=21), G2=pregnantwomenwithmild PE (N=22) and
G3=pregnantwomenwith severe PE (N=20). The normotensive preg-
nant women group (control) had systolic/diastolic blood pressure below
120/80 mm Hg and no history of hypertension or proteinuria. Mild
Table 2
TM, D-Di, cGMP and placental total NOS, Ca++ independent NOS, Ca++ dependent
NOS for the groups studied.
Parameters Group 1
Normotensive
pregnant
Group 2
Mild PE
Group 3
Severe PE
P1 P2 P3
TM 9.4±5.5
(N=21)
8.4±3.1
(N=22)
17.9±8.9
(N=20)
0.340 0.001 0.001
D-Di 1146.6±
311.2
(N=26)
1060.3±
259.2
(N=23)
1497.8±
435.3
(N=20)
0.551 0.001 0.006
cGMP 2.5±0.7 2.1±0.7⁎ 2.2±0.9 0.701 0.902 0.699
227L.M. Dusse et al. / Clinica Chimica Acta 415 (2013) 226–229PEwas characterized by systolic blood pressure≥140 mmHg at admis-
sion, or diastolic ≥90 mm Hg on two or more consecutive occasions,
4 h apart; and proteinuria (either ≥300 mg protein per day or an uri-
nary protein/creatinine ratio ≥30 mg/mmol) occurring after 20th
week of pregnancy in women who had no previous symptoms. Severe
PE was deﬁned by systolic blood pressure ≥160 mm Hg at admission,
or diastolic ≥110 mm Hg on ≥2 consecutive occasions, 4 h apart; and
proteinuria ≥2 g/24 h [11].
Exclusion criteria common for the three groups were chronic hy-
pertension, hemostatic abnormalities, cardiovascular, autoimmune,
renal and hepatic diseases, diabetes and anticoagulant therapy. In ad-
dition, none of the participants had hypertension in previous preg-
nancies. Clinical characteristics of normotensive pregnant, mild and
severe PE are shown in Table 1.
2.2. Samples collection
2.2.1. Blood specimens
Blood samples from pregnant women were collected at the time of
hospital admission under the supervision of the lead author. Blood
were collected into vacutainer tubes containing sodium citrate (Becton-
Dickinson). Following centrifugation at 2800 ×g for 10 min at room
temperature, plasma samples were immediately isolated and stored at
−70 °C for batch-wise analysis in order to reduce inter-assay variability.
2.2.2. Whole placenta
Nitric oxide-synthase activity was assessed in stem villous vessels
from placenta. Samples of placental tissue were taken from normoten-
sive pregnantwomen aswell aswomenwithmild and severe PE, as de-
tailed above. Immediately after placental expulsion and separation four
slices weighing approximately 0.5 g each were diced from the central
part of the placenta which is rich in villous. Subsequently, diced stem
villous vessels were wrapped in aluminum foil, weighed and immedi-
ately, i.e., within few minutes of delivery, stored in liquid nitrogen
until use as previously described [12].
2.3. Assays
2.3.1. Thrombomodulin and D-Dimer
Thrombomodulin and D-Dimer levels were measured in blood
plasma specimens using the IMUBIND®ELISA assays according to
the manufacturer's instructions (American Diagnostica Inc., Stamford,
Connecticut, USA).
2.3.2. Cyclic guanosine monophosphate
Plasma cGMPwas determined using a highly speciﬁc radio immune
assay (AMERSHAM International plc/RPA 525, UK).
2.3.3. Nitric oxide synthase activity assay
Placental NOS activity was assessed by monitoring the conversion
of 14C-L-arginine to 14C-L-Citrulline as previously described [13].
Brieﬂy, after thawing the placental fragment were homogenized
with 100 μl of CHAPS (10 g%), 5 μl of PMSF and 295 μl of homogeni-
zation buffer. The determination of NOS total activity was performedTable 1
Clinical data for the three groups studied.
Groups Normotensive pregnant Mild PE Severe PE
Age 23.08±4.59 22.21±5.19 23.60±5.05
Gestational age 37.19±3.10 35.79±3.11 32.85±3.75
Number of gestation 1 16 (61%) 15 (62%) 10 (50%)
2 4 (15%) 4 (17%) 6 (30%)
3 3 (12%) 4 (17%) 2 (10%)
>3 3 (12%) 1 (4%) 2 (10%)
Systolic blood pressure 100±10 150±10 180±15
Diastolic blood pressure 70±6 102±9 120±17in duplicate (tubes1 and 2) by adding 30 μl of placental villi homog-
enate and 50 μl of assay buffer. As well the activity of NOS Ca+2 inde-
pendent was performed in duplicate (tubes 3 and 4) by adding 30 μl
of placental villi homogenate and 50 μl of assay buffer containing
Ca+2 chelator EGTA 1 mM. To control the reaction inhibition (tubes
5 and 6) 30 μl of homogenate placental villi were added to 50 μl
of assay buffer containing 1 mmol/l EGTA and 1 mmol/l L-NAME
(NOS inhibitor). To control the separation of 14C-L-arginine and 14C-
L-citrulline (tubes 7 and 8), 30 μl of homogenization buffer and
50 μl of assay buffer were added and ﬁnally, for obtaining a total
count provided by the amount of arginine used (tubes 9 and 10),
30 μl of homogenization buffer was added to 50 μl of assay buffer.
All tubes were incubated at 37 °C in a water bath for 20 min. Imme-
diately after the incubation 500 μl of the mixture resin-water was
added to each tube, except in tubes 9 and 10. In these 2 tubes,
500 μl of distilled water was added. Then, all tubes were homoge-
nized gently by inversion, and immediately centrifuged at 2500 rpm
for 2 min at room temperature. Finally, 150 μl of supernatant (from
test-tubes and resin control) was added to 1 ml of scintillation liquid
in the tube itself to perform the count, which was done by using
Packard-USA for 5 min. NOS activity-dependent Ca+2 was obtained
by subtracting the NOS activity-independent Ca+2 (mean values
obtained for the tubes 3 and 4) from the total activity (mean values
obtained for tubes 1 and 2).
2.4. Statistical analysis
Statistical analysis was performed using SIGMA STAT (version 2.03).
Data were normally distributed. Thus, differences between groups
were determined using analysis of variance (ANOVA). Parameter for
which there was a statistical difference during the initial analysis, Fisher
test/LSD (least signiﬁcance Difference) was used. Correlation analyses
were done by Pearson or Spearman tests. Statistical signiﬁcance was
deﬁned at Pb0.05.
3. Results
No difference was found comparing age and gestational age among
the three groups (Table 1). Means±SDs for plasma TM, D-Di, cGMP
and placental total NOS, calcium-independent NOS, calcium-dependent
NOS for the groups studied are shown in Table 2. Plasma TM and D-Di
levelswere higher inwomenwith severe PE compared to normotensive(pmol/mL) (N=23) (N=19) (N=18)
Total NOS
(nmol citrulline/
min/g of protein)
11.7±4.4
(N=20)
9.7±2.1
(N=19)
11.5±5.0
(N=18)
0.775 0.487 0.897
Ca++independent
NOS
(nmol citrulline/
min/g of protein)
2.7±1.9
(N=20)
2.5±1.4
(N=19)
3.5±3.0
(N=18)
0.521 0.916 0.888
Ca++dependent
NOS
(nmol citrulline/
min/g of protein)
9.0±3.8
(N=20)
7.2±1.7
(N=19)
8.0±3.1
(N=18)
0.576 0.787 0.654
Mean±SD. Statistical analysis made by ANOVA/Fisher - LSD.
P1: Group 1×Group 2; P2: Group 2×Group 3; P3: Group 1×Group 3.
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with mild PE (P=0.001 in both cases). However, there was no statisti-
cally signiﬁcant difference when normotensive pregnant women group
was compared towomenwithmild PE. In addition, we observed no sig-
niﬁcant difference among the groups studied for total NOS, calcium in-
dependent NOS, calcium dependent NOS and plasma cGMP levels
(Table 2).
4. Discussion
Normal pregnancy is associated with activation of the hemostatic
system. This is an important protective mechanism against excessive
bleeding during childbirth [14]. Indeed, in our study D-Di levels of nor-
motensive pregnant women were signiﬁcantly higher than the upper
limit of the normal range for D-Di (b400 ng/ml). This is consistent
with previous studies [15,16]. Bellart et al. [17] reported a progressive
increase in D-Di levels throughout gestation which peaked at delivery.
Similarly, plasma TM, amarker for endothelial injury [7], increased dur-
ing the course of normal pregnancy (24–32 weeks) but an earlier and
greater increase was reported to occur in womenwho developed either
gestational hypertension or PE [18]. Recently, our group demonstrated
that plasma TM levels can distinguish women with PE from normoten-
sive pregnant women with considerable sensitivity (70%) and speciﬁc-
ity (60%) [19]. Endothelial injurymay lead to elevated plasma TM levels
[7] andmay contribute to a hypercoagulable state in womenwith PE as
evidenced by raised D-Di levels [20,21].
Maruyama et al. [22] demonstrated TM in arteries, veins, capil-
laries, and lymphatic and on syncytiothrophoblast of human placenta.
Based on it and considering the endothelial injury seen in PE [2], it
was expected to compromise endothelial NO-synthase activity in pla-
cental tissue from preeclamptic women. However, we are not able to
detect reduced activity of this enzyme. Similarly, the other indirect
NO marker investigated, cGMP plasma levels, did not also reveal de-
creased NO synthesis in PE compared to normotensive pregnant.
It is well known that NO determination in biological ﬂuids is a chal-
lenge especially due to its short half-life and concentration [23]. Thus,
indirect markers reﬂecting NO presence have preferentially been used,
largely because they are more simple and cheap to run. In fact, NO syn-
thesis in PE has been investigated by differentmethods but results were
inconsistent. Thus, increased [24–27], decreased [28–32] or unchanged
[33–37] NO synthesis in womenwith PE have been reported. Methodo-
logical shortcomings and sources of specimensmay have contributed to
such ﬁndings. To address such controversies, we assessed NO by two
indirect methods (placental NOS activity and plasma cGMP), but for
both no difference was obtained comparing normotensive pregnant
and preeclamptic women.
Correlation analysis between data showed only a positive correla-
tion between total NOS versus Ca+2 independent NOS, and total NOS
versus Ca+2 dependent NOS for the three groups. It was expected,
since total NOS is the sum of Ca+2 independent and Ca+2 dependent
NOS. A ratio “Ca+2 independent NOS/ Ca+2 dependent NOS”was calcu-
lated for each group (3.33, 2.88 and 2.28 for normotensive pregnant,
mild and severe PE, respectively). This ﬁnding shows a major contribu-
tion of Ca+2 independent NOS in severe PE compared to mild PE and
normotensive pregnant, which suggests a gradual and increased in-
volvement of the inﬂammatory system, consistent with the worse of
the disease.
Although our result did not show difference in NO levels among the
three groups, it does not eliminate the possibility of a reduction in NO
bioavailability in PE. Some hypotheses were raised to clarify NO results
interpretation in studies involving PE. Firstly, the presence of ﬁbrin clot
in placental micro vases can inactivate NO. Our data showed elevated
D-Di levels in PE suggesting exacerbation of coagulation and the
possible presence of ﬁbrin in the vessels. Fibrin deposition in microcir-
culation reduces blood viscosity, compromised red blood motility,
causes hemolysis and ultimately hemoglobin release. Besides, ﬁbrincompromises placental perfusion, leading to membrane detachment
and production of local hemorrhages [5]. NO could react rapidly with
hemoglobin iron instead of the reaction between iron from guanylate
cyclase. The inactivation of NO by hemoglobin iron in PEwas previously
raised by Sarrel et al. [38]. Second, several studies on women with PE
suggested a relationship between enhanced O2− generation and endo-
thelial injury, inﬂammation [39] as well as a decreased superoxide
dismutase [40]. O2− promptly reacts with NO yielding peroxynitrite
(ONOO−) and avoiding the reaction between NO and iron from
guanylate cyclase. Third, optimal conditions were provided for in
vitro NOS activity determination in this study. Thus, if preeclamptic
women have a deﬁciency of L-arginine co-factors (FAD, FMN, BH4 and
NADPH) or calcium ions, NO synthesis will be compromised even if
NOS activity is normal. A relationship between calcium ions deﬁciency
and PE occurrence was previously proposed [41]. PE is associated with
increased asymmetric dimethylarginine (ADMA), which competes
with L-arginine for the binding site of NOS and, consequently, compro-
mises NO synthesis [42,43]. Fifth, it is related to interferences on plasma
cGMP levels. Natrium peptide (ANP) increases cGMP levels [44] and
previous studies showed an increase in ANP in PE [45,46]. Thus, it is pos-
sible that the detected increase in cGMP levels is due to ANP instead of
NO. Studies on cGMP plasma levels in PE were also inconsistent conclu-
sions [26,32,41]. Besides, it is well documented that platelet consump-
tion occurs in PE [47] and platelets also produce cGMP [48]. It is
therefore possible that part of cGMP detected in plasma is from platelet
rather than vascular muscle cells. Finally, it is relevant to note that sys-
temic determination of NO may not reﬂect its local bioavailability;
hence differential production of NO throughout the vascular net was
previously reported [49].
In conclusion, both TM and D-Di levels are raised inwomenwith se-
vere PE compared with women with mild PE and normotensive preg-
nant. While increased TM levels may reﬂect endothelial injury, raised
D-Di levels suggest a hypercoagulable state. NO assessed by two indi-
rectmarkers did not show anymeaningful difference among the groups
studied. Due to current limitations with in vitro NO measurements and
interferences associated to NO bioavailability, particularly in PE, such
ﬁndings should not be over-interpreted.Acknowledgments
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